Posted by Michael Wonder on 29 Apr 2017
European Commission approves Bristol-Myers Squibb’s Opdivo (nivolumab) for squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy
28 April 2017 - This is the first approval in Europe of a treatment for squamous cell cancer of the head and neck in more than a decade.
Bristol-Myers Squibb Company today announced that the European Commission has approved Opdivo (nivolumab) as monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.
Opdivo is the first and only immuno-oncology treatment that demonstrated in a Phase 3 trial a significant improvement in overall survival for these patients.
